Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections

References

• Vallejo-Torres L, Pujol M, Shaw E, et al. Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the Combacte-Magnet, Rescuing study. BMJ Open. 2018;8(4):e020251.
   PubMed Web of Science ®Google Scholar
• Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 Mar 01;28(1):1–13.
   PubMed Web of Science ®Google Scholar
• Bonkat G EAU guideline on urological infections. Edn presented at the EAU annual congress barcelona 2019 ISBN 978-94-92671-04-2 2019.
   Google Scholar
• WHO. Antimicrobial resistance. 2018.
   Google Scholar
• Mangion IK, Ruck RT, Rivera N, et al. A concise synthesis of a β-lactamase inhibitor. Org Lett. 2011;13(20):5480–5483.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027–1052
   PubMed Web of Science ®Google Scholar
• Kahan FM, Kropp H, Sundelof JG, et al. Thienamycin: development of imipenem-cilastatin. J Antimicrob Chemother. 1983;12(supplD):1–35.
   PubMedGoogle Scholar
• Norrby SR, Alestig K, Bjornegard B, et al. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. 1983;23(2):300–307.
   Google Scholar
• Blizzard TA, Chen H, Kim S, et al. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. Bioorg Med Chem Lett. 2014;24(3):780–785
   PubMed Web of Science ®Google Scholar
• Abraham EPCE. An enzyme from bacteria able to destroy penicillin. Rev Infect Dis. 1940;4:677–678.
   Google Scholar
• Bush K, Jacoby GA. Updated functional classification of -lactamases. Antimicrob Agents Chemother. 2010;54(3):969–976.
   PubMed Web of Science ®Google Scholar
• Smith JR, Rybak JM, Claeys KC. Imipenem-cilastatin-relebactam: a novel beta-lactam-beta-lactamase inhibitor combination for the treatment of multidrug-resistant gram-negative infections. Pharmacotherapy. 2020Feb15;40(4):343–356.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations. Drugs. 2018 Jan;78(1):65–98.
   PubMed Web of Science ®Google Scholar
• Lob SH, Karlowsky JA, Young K, et al. In vitro activity of imipenem-relebactam against resistant phenotypes of enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART surveillance Europe 2015-2017. J Med Microbiol. 2020 Feb;69(2):207–217
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, Young K, et al. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016. J Glob Antimicrob Resist. 2018 Dec;15:140–147.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, Young K, et al. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017. Diagn Microbiol Infect Dis. 2019 Oct;95(2):212–215.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Touw DJ, Horrevorts AM, et al. Comparative pharmacokinetics of the carbapenems. 2000;39(3):185–201.
   Google Scholar
• Bhagunde P, Chang KT, Hirsch EB, et al. Novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May;56(5):2237–2240.
   PubMed Web of Science ®Google Scholar
• Wu J, Racine F, Wismer MK, et al. Exploring the pharmacokinetic/pharmacodynamic relationship of relebactam (MK-7655) in combination with imipenem in a hollow-fiber infection model. Antimicrob Agents Chemother. 2018 May;62(5). DOI:10.1128/AAC.02323-17.
   Web of Science ®Google Scholar
• Bhagunde P, Zhang Z, Racine F, et al. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. Inter J Infect Dis. 2019;89:55–61.
   PubMed Web of Science ®Google Scholar
• Bhagunde P, Patel P, Lala M, et al., Population pharmacokinetic analysis for imipenem-relebactam in healthy volunteers and patients with bacterial infections. CPT Pharmacometrics Syst Pharmacol. 8(10): 748–758. 2019
   PubMedGoogle Scholar
• Rhee EG, Rizk ML, Calder N, et al. Pharmacokinetics, safety, and tolerability of single and multiple doses of relebactam, a beta-lactamase inhibitor, in combination with imipenem and cilastatin in healthy participants. Antimicrob Agents Chemother. 2018;62:e00280–18.
   PubMed Web of Science ®Google Scholar
• Rizk ML, Rhee EG, Jumes PA, et al. Intrapulmonary pharmacokinetics of relebactam, a novel beta-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects. Antimicrob Agents Chemother. 2018;62(3):Mar
   Web of Science ®Google Scholar
• Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017 Sep 1;72(9):2616–2626
   PubMed Web of Science ®Google Scholar
• Sharp M, Dohme BV Summary of product characteristics Recarbrio.
   Google Scholar
• Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016 Oct;60(10):6234–6243
   PubMed Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clinl Infect Dis. 2020 Apr 15;70(9):1799–1808
   PubMed Web of Science ®Google Scholar
• Titov I, Wunderink RG, Roquilly A, et al. RESTORE-IMI 2: randomised, double-blind, phase III trial comparing efficacy and safety of imipenem/cilastatin (IMI)/relebactam (REL) versus piperacillin/tazobactam (PIP/TAZ) in adult patients with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP). Abstract 771, European congress of clinical microbiology and infectious diseases. Paris. 2020.
   Google Scholar
• Cannon JP, Lee TA, Clark NM, et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother. 2014;69(8):2043–2055.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assesment report recarbrio. 12 December 2019.
   Google Scholar